Drug Approval | October 02, 2024
Aurobindo Pharma receives USFDA approval for Cephalexin Tablets
The product is expected to be launched in Q3FY25
The product is expected to be launched in Q3FY25
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
He holds a Master’s in Management from the National University of Singapore
The observations are of procedural in nature and will be responded to within the stipulated time
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Subscribe To Our Newsletter & Stay Updated
